Related Experiment Videos
[Therapy with interleukin 2 for chronic viral hepatitis]
1Third Department of Internal Medicine, Osaka City University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 1, 1992
Summary
Recombinant interleukin 2 (r-IL2) therapy showed promise for chronic hepatitis B by boosting the immune system and reducing viral activity. This biological response modifier effectively lowered viral markers and improved patient immune responses.
Area of Science:
- Immunology
- Virology
- Hepatology
Context:
- Chronic hepatitis B infection remains a significant global health challenge.
- Hepatitis B virus (HBV) persistence is often associated with immune dysfunction.
- Serum HBe antigen positivity indicates active viral replication and infectivity.
Purpose:
- To evaluate the efficacy of recombinant interleukin 2 (r-IL2) as an immunostimulant in patients with chronic hepatitis B.
- To assess the impact of r-IL2 therapy on viral markers and immune parameters in HBeAg-positive individuals.
- To determine the potential of r-IL2 as a biological response modifier (BRM) for chronic hepatitis B.
Summary:
- Patients received r-IL2 (250-10,000 U) intravenously or intramuscularly for 1-4 weeks.
- Therapy led to transient increases in ALT, followed by decreases; HBV DNA polymerase activity became undetectable in 6/11 cases.
- Serum HBeAg levels decreased, anti-HBe antibodies increased, and immune cell counts (lymphocytes, eosinophils) showed transient changes.
Impact:
- r-IL2 therapy demonstrated utility in managing chronic hepatitis B by modulating the immune system.
- The study suggests r-IL2 can be considered as an immunostimulant or BRM for HBeAg-positive chronic hepatitis B.
- Findings contribute to understanding immunotherapeutic approaches for chronic viral infections.